Literature DB >> 24084736

Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.

Susannah D Brydges, Lori Broderick, Matthew D McGeough, Carla A Pena, James L Mueller, Hal M Hoffman.   

Abstract

The inflammasome is a cytoplasmic multiprotein complex that promotes proinflammatory cytokine maturation in response to host- and pathogen-derived signals. Missense mutations in cryopyrin (NLRP3) result in a hyperactive inflammasome that drives overproduction of the proinflammatory cytokines IL-1β and IL-18, leading to the cryopyrin-associated periodic syndromes (CAPS) disease spectrum. Mouse lines harboring CAPS-associated mutations in Nlrp3 have elevated levels of IL-1β and IL-18 and closely mimic human disease. To examine the role of inflammasome-driven IL-18 in murine CAPS, we bred Nlrp3 mutations onto an Il18r-null background. Deletion of Il18r resulted in partial phenotypic rescue that abolished skin and visceral disease in young mice and normalized serum cytokines to a greater extent than breeding to Il1r-null mice. Significant systemic inflammation developed in aging Nlrp3 mutant Il18r-null mice, indicating that IL-1 and IL-18 drive pathology at different stages of the disease process. Ongoing inflammation in double-cytokine knockout CAPS mice implicated a role for caspase-1-mediated pyroptosis and confirmed that CAPS is inflammasome dependent. Our results have important implications for patients with CAPS and residual disease, emphasizing the need to explore other NLRP3-mediated pathways and the potential for inflammasome-targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24084736      PMCID: PMC3809806          DOI: 10.1172/JCI71543

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

Review 1.  Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells.

Authors:  Susan L Fink; Brad T Cookson
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

2.  IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients.

Authors:  Jeffrey H Stack; Kevin Beaumont; Paul D Larsen; Kimberly S Straley; Greg W Henkel; John C R Randle; Hal M Hoffman
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

3.  Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation.

Authors:  Ilona Gutcher; Eduard Urich; Karina Wolter; Marco Prinz; Burkhard Becher
Journal:  Nat Immunol       Date:  2006-08-13       Impact factor: 25.606

4.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

5.  Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome.

Authors:  Karin Mazodier; Valérie Marin; Daniela Novick; Catherine Farnarier; Stéphane Robitail; Nicolas Schleinitz; Véronique Veit; Pascale Paul; Menachem Rubinstein; Charles A Dinarello; Jean-Robert Harlé; Gilles Kaplanski
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

6.  Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response.

Authors:  D Novick; S H Kim; G Fantuzzi; L L Reznikov; C A Dinarello; M Rubinstein
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

Review 7.  Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis.

Authors:  Roy Fleischmann; Richard Stern; Imran Iqbal
Journal:  Expert Opin Biol Ther       Date:  2004-08       Impact factor: 4.388

Review 8.  Interleukin-18 and host defense against infection.

Authors:  Charles A Dinarello; Giamila Fantuzzi
Journal:  J Infect Dis       Date:  2003-06-15       Impact factor: 5.226

9.  Differences in signaling pathways by IL-1beta and IL-18.

Authors:  Jae-Kwon Lee; Soo-Hyun Kim; Eli C Lewis; Tania Azam; Leonid L Reznikov; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

10.  Distinct licensing of IL-18 and IL-1β secretion in response to NLRP3 inflammasome activation.

Authors:  Rebecca L Schmidt; Laurel L Lenz
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more
  87 in total

Review 1.  Regulation of inflammasome activation.

Authors:  Si Ming Man; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

Review 2.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

3.  Regulation of epithelial injury and bile duct obstruction by NLRP3, IL-1R1 in experimental biliary atresia.

Authors:  Li Yang; Tatsuki Mizuochi; Pranavkumar Shivakumar; Reena Mourya; Zhenhua Luo; Sridevi Gutta; Jorge A Bezerra
Journal:  J Hepatol       Date:  2018-06-08       Impact factor: 25.083

Review 4.  Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease.

Authors:  Holly Anderton; Ian P Wicks; John Silke
Journal:  Nat Rev Rheumatol       Date:  2020-07-08       Impact factor: 20.543

5.  cASCading specks.

Authors:  Lori Broderick; Hal M Hoffman
Journal:  Nat Immunol       Date:  2014-08       Impact factor: 25.606

6.  Inflammasome activation leads to Caspase-1-dependent mitochondrial damage and block of mitophagy.

Authors:  Jiujiu Yu; Hajime Nagasu; Tomohiko Murakami; Hai Hoang; Lori Broderick; Hal M Hoffman; Tiffany Horng
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

Review 7.  The NLRP3 Inflammasome: An Important Driver of Neuroinflammation in Hemorrhagic Stroke.

Authors:  Shao-Jun Yang; Gao-Feng Shao; Jiang-Li Chen; Jie Gong
Journal:  Cell Mol Neurobiol       Date:  2017-07-27       Impact factor: 5.046

8.  Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis.

Authors:  Scott B Drutman; Filomeen Haerynck; Franklin L Zhong; David Hum; Nicholas J Hernandez; Serkan Belkaya; Franck Rapaport; Sarah Jill de Jong; David Creytens; Simon J Tavernier; Katrien Bonte; Sofie De Schepper; Jutte van der Werff Ten Bosch; Lazaro Lorenzo-Diaz; Andy Wullaert; Xavier Bossuyt; Gérard Orth; Vincent R Bonagura; Vivien Béziat; Laurent Abel; Emmanuelle Jouanguy; Bruno Reversade; Jean-Laurent Casanova
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 9.  Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome.

Authors:  Inna S Afonina; Zhenyu Zhong; Michael Karin; Rudi Beyaert
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

10.  NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice.

Authors:  Alexander Wree; Matthew D McGeough; Maria Eugenia Inzaugarat; Akiko Eguchi; Susanne Schuster; Casey D Johnson; Carla A Peña; Lukas J Geisler; Bettina G Papouchado; Hal M Hoffman; Ariel E Feldstein
Journal:  Hepatology       Date:  2017-12-28       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.